DK0689449T3 - Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin - Google Patents

Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin

Info

Publication number: DK0689449T3
Authority: DK; Denmark
Prior art keywords: pct; cytokine; muramyl peptide; preparations; combining
Prior art date: 1993-03-19

Application number

DK94910445T

Other languages

English (en)

Inventor

Louis Chedid

Georges Bahr

Pierre Lefrancier

Original Assignee

Vacsyn Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-19

Filing date

1994-03-21

Publication date

2003-03-03

1993-03-19 Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr

1993-03-31 Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr

1994-03-21 Application filed by Vacsyn Sa filed Critical Vacsyn Sa

2003-03-03 Application granted granted Critical

2003-03-03 Publication of DK0689449T3 publication Critical patent/DK0689449T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK94910445T 1993-03-19 1994-03-21 Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin DK0689449T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9303230A FR2702659B1 (fr)	1993-03-19	1993-03-19	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr)	1993-03-31	1993-03-31	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
PCT/FR1994/000307 WO1994021275A1 (fr)	1993-03-19	1994-03-21	Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine

Publications (1)

Publication Number	Publication Date
DK0689449T3 true DK0689449T3 (da)	2003-03-03

Family

ID=26230187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94910445T DK0689449T3 (da)	1993-03-19	1994-03-21	Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin

Country Status (11)

Country	Link
US (1)	US5932208A (da)
EP (1)	EP0689449B1 (da)
JP (1)	JP3723206B2 (da)
AT (1)	ATE226828T1 (da)
AU (1)	AU6285694A (da)
CA (1)	CA2157758A1 (da)
DE (1)	DE69431620T2 (da)
DK (1)	DK0689449T3 (da)
ES (1)	ES2187520T3 (da)
PT (1)	PT689449E (da)
WO (1)	WO1994021275A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US6267968B1 (en) *	1995-04-07	2001-07-31	Vacsyn S.A.	MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
EP2002846B1 (en)	1996-12-06	2017-01-25	Amgen Inc.	Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013253A (en) *	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
SK288201B6 (sk)	2000-03-31	2014-06-03	Purdue Research Foundation	Farmaceutický prostriedok
FR2809106A1 (fr) *	2000-05-17	2001-11-23	Istac	Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
EP1414517A4 (en) *	2001-06-26	2008-02-06	Photomed Technologies Inc	MULTIPLE WAVELENGTH ILLUMINATOR
PT2087908T (pt)	2001-06-26	2018-07-16	Amgen Inc	Anticorpos contra opgl
ATE451935T1 (de) *	2001-09-28	2010-01-15	Purdue Research Foundation	Behandlungsverfahren mit liganden- immunogenkonjugaten
US20030097409A1 (en) *	2001-10-05	2003-05-22	Hungchou Tsai	Systems and methods for securing computers
EA033750B1 (ru)	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
WO2004060911A2 (en) *	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
US7546638B2 (en) *	2003-03-18	2009-06-09	Symantec Corporation	Automated identification and clean-up of malicious computer code
MXPA06005451A (es)	2003-11-17	2007-01-26	Biomarin Pharm Inc	Metodos y composiciones para el tratamiento de trastornos metabolicos.
MX2007005039A (es) *	2004-11-17	2007-06-19	Biomarin Pharm Inc	Formulacion de tableta estable.
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8168164B2 (en) *	2006-02-03	2012-05-01	Purdue Research Foundation	Targeted conjugates and radiation
US7833527B2 (en)	2006-10-02	2010-11-16	Amgen Inc.	Methods of treating psoriasis using IL-17 Receptor A antibodies
US8323635B2 (en)	2007-11-14	2012-12-04	General Regeneratives, Ltd.	Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en)	2011-07-22	2014-08-21	Amgen Inc.	Il-17 receptor a is required for il-17c biology
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
US20160000936A1 (en)	2014-06-10	2016-01-07	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en)	2016-07-29	2018-02-01	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en)	2018-08-13	2020-02-20	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en)	2022-05-16	2023-11-23	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
EP4411592B1 (de)	2023-02-06	2025-04-02	Sick Ag	Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK585886A (da) *	1985-12-24	1987-06-25	Takeda Chemical Industries Ltd	Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) *	1986-08-13	1987-12-31	Takeda Chemical Industries Ltd	Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) *	1988-02-13	1988-03-16	Ciba Geigy Ag	Antiviral combination

1994
- 1994-03-21 CA CA002157758A patent/CA2157758A1/en not_active Abandoned
- 1994-03-21 ES ES94910445T patent/ES2187520T3/es not_active Expired - Lifetime
- 1994-03-21 PT PT94910445T patent/PT689449E/pt unknown
- 1994-03-21 DE DE69431620T patent/DE69431620T2/de not_active Expired - Fee Related
- 1994-03-21 JP JP52072694A patent/JP3723206B2/ja not_active Expired - Fee Related
- 1994-03-21 WO PCT/FR1994/000307 patent/WO1994021275A1/fr active IP Right Grant
- 1994-03-21 AU AU62856/94A patent/AU6285694A/en not_active Abandoned
- 1994-03-21 AT AT94910445T patent/ATE226828T1/de not_active IP Right Cessation
- 1994-03-21 DK DK94910445T patent/DK0689449T3/da active
- 1994-03-21 US US08/522,342 patent/US5932208A/en not_active Expired - Fee Related
- 1994-03-21 EP EP94910445A patent/EP0689449B1/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2187520T3 (es)	2003-06-16
WO1994021275A1 (fr)	1994-09-29
CA2157758A1 (en)	1994-09-29
PT689449E (pt)	2003-03-31
DE69431620T2 (de)	2003-07-03
DE69431620D1 (de)	2002-12-05
US5932208A (en)	1999-08-03
JPH08511235A (ja)	1996-11-26
EP0689449A1 (fr)	1996-01-03
EP0689449B1 (fr)	2002-10-30
ATE226828T1 (de)	2002-11-15
AU6285694A (en)	1994-10-11
JP3723206B2 (ja)	2005-12-07

Publication	Publication Date	Title
DK0689449T3 (da)	2003-03-03	Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin
CA1288694C (en)	1991-09-10	Process for treatment of diseases
O'Suilleabhain et al.	1996	Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury
IT1261949B (it)	1996-06-04	Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
KR950700333A (ko)	1995-01-16	개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
DK0751992T3 (da)	2006-03-06	Karendotelvækstfaktor 2
EP0787802A3 (da)	1997-08-27
DE69428214D1 (de)	2001-10-11	Transformierender wachstumsfaktor alpha h1
DE59507920D1 (de)	2000-04-06	NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DK0669979T3 (da)	2006-03-06	C-C CKR-1, kemokinreceptor
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NZ516477A (en)	2004-02-27	Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DE59209196D1 (de)	1998-03-19	Menschliche il-4 mutantenproteine
NO964200L (no)	1996-10-03	Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
SE9201966D0 (sv)	1992-06-25	Interleukin-1beta deletion mutant
NO915084L (no)	1992-06-29	Fremgangsmaate ved fremstilling av human interleukin-5 receptor
HUP0000248A2 (hu)	2000-06-28	Nagy affinitású interleukin-4 muteinek
CA2388338A1 (en)	2001-05-03	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
NO971378L (no)	1997-06-05	Cytokin betegnet LERK-6
NZ504955A (en)	2002-11-26	The use of TH1 and TH2 cytokines for the preparation of an oromucosal medicament
DE69127974D1 (de)	1997-11-20	Peptide und deren verwendung
ATE442387T1 (de)	2009-09-15	Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
HK1015708A1 (en)	1999-10-22	Use of muteins of wild-type cytokines as immunogens.
WO2000009150A3 (en)	2000-05-11	Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
NZ332690A (en)	2000-07-28	Stimulation of host defence mechanisms against viral challenges using interferon